M B. Wagenaar-Muntinghe

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

Journal: Cancer communications (London, England)

Published: November 03, 2025

Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.

Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.

Journal: Targeted oncology

Published: May 07, 2025

Reply to Letter to the Editor "Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study" by Liu et al., G. Rocco, and Szarpak et al.

Reply to Letter to the Editor "Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study" by Liu et al., G. Rocco, and Szarpak et al.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 06, 2025

Lung cancer detection by electronic nose analysis of exhaled breath: a multicentre prospective external validation study.

Lung cancer detection by electronic nose analysis of exhaled breath: a multicentre prospective external validation study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 23, 2025

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

Journal: Translational lung cancer research

Published: October 18, 2024

Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC.

Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 25, 2024

Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.

Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.

Journal: Cancers

Published: June 21, 2024

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).

Journal: Frontiers in oncology

Published: January 02, 2023

Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial.

Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 10, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026